Display Settings:

Format

Send to:

Choose Destination

    J Pediatr Gastroenterol Nutr. 1994 Feb;18(2):134-41.

    Clinical and biochemical findings in progressive familial intrahepatic cholestasis.

    Whitington PF, Freese DK, Alonso EM, Schwarzenberg SJ, Sharp HL.

    Department of Pediatrics, University of Chicago Pritzker School of Medicine, Illinois.

    The clinical findings in 33 patients with progressive familial intrahepatic cholestasis (PFIC) are presented. Symptoms developed almost invariably before 6 months of age with severe pruritus and moderate jaundice. Other clinical findings included wheezing and nosebleeds, fat-soluble vitamin deficiency states, and cholelithiasis. Lower values for gamma-glutamyl transpeptidase, averaging 15 IU/L before the administration of phenobarbital, and cholesterol, which averaged 156 mg/dl, are helpful in distinguishing PFIC from other pediatric cholestatic liver diseases. Autosomal recessive inheritance is probable. Twenty-six patients are alive at 12.9 +/- 6.7 years of age, all having had successful surgical treatment, either partial biliary diversion (n = 17) or orthotopic liver transplantation (n = 10). Seven patients died at a mean age of 3.9 +/- 2.4 years, as a result of liver failure in two, hepatocellular carcinoma in two, and complications of liver transplantation in three.

    PMID: 7912266 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    • Phenobarbital (Luminal® Sodium)

      Phenobarbital, a barbiturate, is used to control epilepsy (seizures) and as a sedative to relieve anxiety. It is also used for short-term treatment of insomnia to help you fall asleep.